MOTS-c
Mitochondrial-derived peptide
The Ground Truth Score
four plain questions, never one numberStriking in mice, barely tested
Bottom line
One of the most exciting longevity peptides in animal research, and one of the least tested in humans, where the very first clinical trial only began in 2026.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported, not prescribed, and explicitly experimental.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No human results exist. The first registered human clinical trial, a Phase 1 insulin-sensitivity study, was registered in 2026 and has no completed data.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Acts as an 'exercise mimetic,' improving metabolism and endurance.
- Improves insulin sensitivity and metabolic health.
- May slow aspects of aging at the cellular level.
The data behind each bullet
What actually backs it
Exercise mimetic / boosts endurance.
In aged mice, MOTS-c roughly doubled running capacity. No human performance data exists.
Aged-mouse endurance study ↗Improves insulin sensitivity.
Strong animal and mechanistic data on glucose metabolism; the first human trial testing exactly this began in 2026 with no results yet.
First-in-human trial. ClinicalTrials.gov ↗Slows cellular aging.
A 2025 mechanistic paper reported MOTS-c prevents pancreatic islet-cell senescence in a model. This is a laboratory mechanism, not a human outcome.
Senescence mechanism paper (2025) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed, with striking animal support: MOTS-c is a peptide encoded inside mitochondrial DNA that activates AMPK, a master metabolic switch, and antioxidant gene programs, behaving like an exercise mimetic. The first human trial only began in 2026.
Dosing & handling
What users and clinicians report
Reported, not prescribed, and explicitly experimental. Community and research protocols cite 5–10 mg subcutaneously, 3–5× per week. There is no established clinical dose.
This is a compound whose first human trial is ongoing. Any dose is a guess informed by mouse studies.
Timing & food
Community and research protocols: 2–5× per week, often in the morning and fasted, on the rationale that it's an 'exercise-mimetic' tied to metabolism. The exact timing is unestablished.
Half-life
Not well characterized in humans; research and community protocols dose several times weekly. Its development was historically slowed by stability and delivery challenges.
Reconstitution sensitivity
Standard peptide fragility, refrigerate, don't shake. Stability has been a real formulation problem for this one, so handling care matters more than most.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Thin first-person corpus, most indexed MOTS-c content is vendor SEO and academic papers, not user logs.
Consistency
Only one lived claim converges (endurance / work capacity); metabolic and fat-loss claims are sparse, mixed, and stack-confounded.
Source credibility
If you only read the blogs you'd massively overrate it; the real ledger (MESO-Rx, including 'doing absolutely nothing' threads) is small.
- Reported uses center on metabolic health, endurance, and fat loss, usually by people already optimizing hard.
- Reports are enthusiastic but sparse, and very hard to separate from training and diet.
- Few side-effect reports; the honest read is 'not enough people have used it carefully to know.'
Placebo risk, Low
What people chase here, insulin sensitivity, endurance, fat loss, is objective and measurable, so placebo can't fake it. The catch is almost nobody is actually measuring.
Risk panel
What could go wrong
Adverse events
Unknown in humans receiving it exogenously, no one has been formally studied yet.
Theoretical concerns
As a naturally occurring signaling peptide, the theoretical profile is reassuring, but 'endogenous' does not mean 'safe at injected doses.'
Contraindications
Undefined, there is no human safety dataset to derive them from.
Honest unknowns
Effective dose, route, durability, drug interactions, and essentially all human safety.
Confound watch
MOTS-c is popular with people already optimizing hard, training, GLP-1s, caloric control. Any metabolic improvement they report is hopelessly entangled with those much-better-evidenced variables.
History
Discovery → first use → status
Heads up: the legal status is moving (2026)
This one got put on the FDA's Category 2 'do not compound' list back in 2023. In April 2026 the FDA moved to pull it back off that list, and there's a July 2026 advisory meeting weighing whether it can be legally compounded again. None of that is final, and none of it makes anything proven or safe. It just means the legal picture is changing fast, so check the date on anything you read about whether this is allowed.
FDA peptide compounding update, 2026 ↗- 2015MOTS-c identified as a peptide encoded within mitochondrial DNA.
- 2015–2025Animal and in-vitro work shows metabolic and endurance effects; development slowed by delivery and stability challenges.
- 2025Mechanistic paper links MOTS-c to delayed islet-cell senescence.
- Apr 2026First-in-human Phase 1 trial registered, no completed data yet.
- Apr 23 2026Removed from FDA Category 2; PCAC review scheduled Jul 23 2026.
Verification
The COA standard, applied
Injected, so the full standard applies: HPLC ≥98%, mass-spec identity, LAL endotoxin, from an independent lab. Identity verification is especially important for an expensive peptide that is easy to under-fill or substitute.
The full verification standard →Sources
Where this comes from
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.